Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 211–220 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 211
- Medicine slug
- budesonide
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 51
- Source count
- 38
- Agreement rate
- 0.657895
- Recorded readings
3 L/kg
- Numeric value
- 3
- Unit
- L/kg
- Source records
- 25
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 25 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2414058b-5d39-42f2-915f-03a5e1101ab5 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4 to 6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e8a6cf4-4bda-4e22-8653-12635adfb316 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4 to 6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7df2a10-4166-423e-bb60-5f3a8234f26c (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4 to 6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8ef9489-83a2-4817-b21c-ea3fecd8c8dd (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4 to 6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10ea5d87-6ed0-4fa5-a37b-2043c8560bc0 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of budesonide was approximately 3 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32e30f11-e19b-4e23-a893-92d95e48edef (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4 to 6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a7d97e0-36f7-4ac9-8f9b-4c3aac568c2b (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4 to 6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:521a79d0-4d93-45f7-8feb-8d2b502dd216 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4 to 6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c70c734f-2431-4414-bb94-4adda4985e5d (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4 to 6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d139a25-9c17-4b3e-8ffd-b2d562cc00ee (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4 to 6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c52c5382-1400-44b9-95be-a30e1cf706da (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4-6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:374013c9-18c9-4419-b9fb-9bc5c765688e (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4 to 6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae1105cd-69fc-4c15-937f-c535304341c2 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of budesonide was approximately 3 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79fc8cf4-bb33-4892-9dd2-641d7e943a01 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of budesonide was approximately 3 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f126a29-38f7-4c4c-8978-37e72b289902 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4 to 6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f12043df-f9a3-4edb-88f8-dd176c1a141c (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4 to 6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a39fbcfc-3ffd-44bd-b882-01f8e1844213 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4 to 6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d406759d-4c02-4fc0-b513-56b303afca98 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4 to 6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10f2ae5b-a6fb-4804-9111-0cd067c2b1b2 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of budesonide was approximately 3 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d90ffda1-12c7-4726-90e9-64bb103e84b5 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4 to 6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcb35488-23c5-4e7b-ab86-8406cf855748 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4-6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d0c6c7e-2f53-4238-ab34-bd8cf49d8a66 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of budesonide was approximately 3 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9656442-4587-4867-9a8c-5f5b0402936e (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4-6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33cd9834-76df-4f26-3fa2-aab6b9eee8f2 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4-6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3235e2a4-8e12-2d58-e063-6294a90a4936 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution: In asthmatic children 4 to 6 years of age, the volume of distribution at steady-state of budesonide was 3 L/kg, approximately the same as in healthy adults.
2.2 ± 0.4 L/kg
- Numeric value
- 2.2
- Unit
- L/kg
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a8e79df-3946-4e9a-b214-e9fdd824b565 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
After single dose administration of intravenous budesonide (n=4), the mean volume of distribution (V ss ) was 2.2 ± 0.4 L/kg and mean clearance was 0.81 ± 0.2 L/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33def4dc-b469-f987-e063-6294a90ace0b (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
After single dose administration of intravenous budesonide (n=4), the mean volume of distribution (V ss ) was 2.2 ± 0.4 L/kg and mean clearance was 0.81 ± 0.2 L/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:263303c2-8e4f-7b6c-e063-6394a90aef9e (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
After single dose administration of intravenous budesonide (n=4), the mean volume of distribution (V ss ) was 2.2 ± 0.4 L/kg and mean clearance was 0.81 ± 0.2 L/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4943ef5b-f48b-49d6-b419-467f71ef64e0 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
After single dose administration of intravenous budesonide (n=4), the mean volume of distribution (V ss ) was 2.2 ± 0.4 L/kg and mean clearance was 0.81 ± 0.2 L/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b15102d5-7884-44ed-8340-046d7b516fa8 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
After single dose administration of intravenous budesonide (n=4), the mean volume of distribution (V ss ) was 2.2 ± 0.4 L/kg and mean clearance was 0.81 ± 0.2 L/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a37866df-df07-4f71-8591-98c2804c4794 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
After single dose administration of intravenous budesonide (n=4), the mean volume of distribution (V ss ) was 2.2 ± 0.4 L/kg and mean clearance was 0.81 ± 0.2 L/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10336e42-0e9d-45c4-80bc-5149d5ec9e1c (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
After single dose administration of intravenous budesonide (n = 4), the mean volume of distribution (V ss ) was 2.2 ± 0.4 L/kg and mean clearance was 0.81 ± 0.2 L/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a18d5a7-04c5-4137-8155-70a8adc0a48b (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
After single dose administration of intravenous budesonide (n=4), the mean volume of distribution (V ss ) was 2.2 ± 0.4 L/kg and mean clearance was 0.81 ± 0.2 L/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7aca8d1-159e-4aac-b92d-3a69a8edceec (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
After single dose administration of intravenous budesonide (n=4), the mean volume of distribution (V ss ) was 2.2 ± 0.4 L/kg and mean clearance was 0.81 ± 0.2 L/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29863154-5f98-410e-9bf3-0f08b551edef (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
After single dose administration of intravenous budesonide (n=4), the mean volume of distribution (V ss ) was 2.2 ± 0.4 L/kg and mean clearance was 0.81 ± 0.2 L/min.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e39c491-2793-410e-b77f-8b3cbe9b6231 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
After single dose administration of intravenous budesonide (n=4), the mean volume of distribution (V ss ) was 2.2 ± 0.4 L/kg and mean clearance was 0.81 ± 0.2 L/min.
1886 L
- Numeric value
- 1,886
- Unit
- L
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56f2023a-69b2-4470-b4ad-af7ec1be527a (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Distribution The mean volume of distribution (V ss /F) of budesonide is 1886 L after repeated oral administration of EOHILIA.
3 to 4 L/kg
- Numeric value
- 3
- Unit
- L/kg
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:938cada4-d6bf-4252-836f-dd40f9eadb4d (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The volume of distribution at steady state reported in the literature is 3 to 4 L/kg.
Projected row 212
- Medicine slug
- bumetanide
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 74
- Source count
- 74
- Agreement rate
- 0.986486
- Recorded readings
6 hours
- Numeric value
- 6
- Unit
- hours
- Source records
- 73
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 73 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae7dd557-f7a1-4d5a-b80e-3ca3a6e4943b (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4326e53-5217-48d4-a089-1184442049ac (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12b9489a-b16b-4504-a660-e66fd5261069 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf29e436-b630-4b03-bb9b-9267ae77dc00 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d1ed6b2-c410-4f52-9b8a-aa256c37089e (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e9633e4-151b-4f40-885e-8f364f6f2d18 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2dcdf9b-70b9-493f-99b4-fc7dcc31939a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e3d3ea1-830f-4fc6-9c56-b2ec71875dc6 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9188ab17-8539-48a5-905f-ad35ab5a0b93 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:056be255-5880-48e9-b160-bd5b3d82c24a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94078edd-b9c0-449e-baaf-a9afceccb407 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51d5f639-5d25-4ada-8bbe-ada2386173bf (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fb78afc-d8bc-4ae8-8c0a-6d9c6f7a22c5 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32dfbea3-eb2b-4070-8605-57ce3e6d5a2f (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14e92f79-2c7b-4ab9-844f-e7bd1964f8b2 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:680563fe-5d3a-49bc-86a5-740bda2acebe (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa4e5faf-c91a-457b-bd2b-14a9add51ac8 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4dd156d-0f17-43d9-bf78-2d358c50681b (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79b77945-74a7-4cb5-8aa0-33a7babdf6d9 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51a344b6-acf9-4ac4-b743-1e63e3df7958 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a007f3aa-3977-4be3-a9a2-db3d458bca58 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bed63fb-91ec-4132-ac0a-16c4c6f58d95 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80fe034e-01b7-438e-8378-44fafb7a1d94 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32c4372e-54ea-4fc8-b9f8-827fa4c8edd3 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8e243c0-805a-4d81-bec9-f5be6eb9f2bc (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7c3c63e-3aea-4b33-b165-7c7449359674 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 to 11 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a29cf117-00d0-4948-b646-013c8791ea39 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:551918e1-96c4-453a-870c-61b282882206 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de008936-e8a3-4e65-bb6a-d925b68a5f50 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fb6d547-9966-4352-8974-d02ea58e6445 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:084b34ad-36ba-43bd-a43a-1f4b4da26d8f (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b92460e-48ba-44bb-9b61-5e65e5fd82cd (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5d87c7c-3d03-4a9a-8f07-382371c55169 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8914d8bf-61b7-4cd2-a8ef-7e1c5df37828 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06745425-e7e7-4413-b9ff-22b121f0ea9a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a9229c8-89ba-423e-8e36-f56bc329ed38 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:681b5e9d-e2c7-4f29-aaad-e06d4a528c11 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 to 11 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7cd724b-817b-4b45-8133-1ebf505867e7 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3d38c1d-9b35-478e-bc2f-3e82b09a1538 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b5450f2-ae91-48b6-ad83-261bdfcf47ac (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e47e7b1-d28a-4e12-882f-cf193b7f2697 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d85bbced-8a9e-414d-bc88-dd0b68c118df (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37179b2d-6589-40d8-8121-7561a6791d38 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c753aae-77b7-4add-8453-385a8f62d7db (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef5fe12a-f8ee-4ba7-932b-51bbaccf6575 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:308c690f-c2bd-4c32-8728-42ec95425f77 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 to 11 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f9dccf8-37ff-454b-9d55-7f1d631c8483 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a60bfe5f-d0d6-4d15-a3de-32dc68e41af3 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:525138cd-832a-41d0-84b0-83921b12bd2a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5a68154-8003-4b80-81e2-e926524fb72c (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 to 11 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c71a17e-ed76-4545-b23e-9f4997b13c2f (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87385a0a-e7e6-8b7f-e053-2991aa0aa21a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05cb961d-ac33-4bcf-b04e-411e496c43c1 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bd4fcd3-3020-41f2-b112-023b5db4487d (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:627c9732-eed1-4435-8d79-2e19ab974fd9 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c38a404d-a919-4a2c-9fbb-d0655dee9516 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a5577f5-d2fe-4b0d-8245-78ee77df30fd (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b338ae20-fc07-4ec5-9e68-be636f75ce1a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:387edfd4-be85-41cd-8a6d-14e6a022b5a9 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82eb62ca-c32b-4ff8-9f71-43219b240480 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6f12a41-ae6d-4ce6-9bb1-e32679af665f (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfa1f77d-8209-48e9-a6c7-d3b4725a97db (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7068f36-a863-4af0-9c82-e5394a6e7a54 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cddd33fb-25b0-49ca-ab32-7c79a9b3a384 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bd7a71e-0e78-dae7-e053-2995a90ad110 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 to 11 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6ff0d37-c67d-4b9f-8b62-5deda9783c28 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bcc6cdb-3dfa-4757-bac2-a2dc8bd3a9f6 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b5a38cc-1e76-4821-b286-31bad3bd6913 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43ab2dd6-39ba-4a53-aa84-d7975038ef43 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4688d53-9baf-4cf0-b37f-47779bce7815 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68f18d36-ffc2-4481-9286-914cfcf573a0 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff5dc8c6-b2f2-41d3-8e56-a953aa721b59 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours, with a range up to 15 hours and a serum clearance ranging from 0.2 mL/min/kg to 1.1 mL/min/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9058fc52-f3f6-4d7f-b2a0-b1e2c714b133 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Small pharmacokinetic studies of intravenous bumetanide in preterm and full-term neonates with respiratory disorders have reported an apparent half-life of approximately 6 hours with a range up to 15 hours and a serum clearance ranging from 0.2 to 1.1 mL/min/kg.
1 to 1.5 hours
- Numeric value
- 1
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6f752c5-d2bd-4f77-9611-ca2110066d1f (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Elimination Bumetanide is eliminated rapidly in humans following both oral and parenteral (intravenous or intramuscular) administration, with a half-life of 1 to 1.5 hours.
Projected row 213
- Medicine slug
- bumetanide
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 74
- Source count
- 74
- Agreement rate
- 1
- Recorded readings
94%
- Numeric value
- 94
- Unit
- %
- Source records
- 74
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 74 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae7dd557-f7a1-4d5a-b80e-3ca3a6e4943b (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4326e53-5217-48d4-a089-1184442049ac (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12b9489a-b16b-4504-a660-e66fd5261069 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf29e436-b630-4b03-bb9b-9267ae77dc00 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d1ed6b2-c410-4f52-9b8a-aa256c37089e (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e9633e4-151b-4f40-885e-8f364f6f2d18 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2dcdf9b-70b9-493f-99b4-fc7dcc31939a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e3d3ea1-830f-4fc6-9c56-b2ec71875dc6 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9188ab17-8539-48a5-905f-ad35ab5a0b93 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:056be255-5880-48e9-b160-bd5b3d82c24a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94078edd-b9c0-449e-baaf-a9afceccb407 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51d5f639-5d25-4ada-8bbe-ada2386173bf (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fb78afc-d8bc-4ae8-8c0a-6d9c6f7a22c5 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32dfbea3-eb2b-4070-8605-57ce3e6d5a2f (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14e92f79-2c7b-4ab9-844f-e7bd1964f8b2 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:680563fe-5d3a-49bc-86a5-740bda2acebe (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa4e5faf-c91a-457b-bd2b-14a9add51ac8 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4dd156d-0f17-43d9-bf78-2d358c50681b (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79b77945-74a7-4cb5-8aa0-33a7babdf6d9 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51a344b6-acf9-4ac4-b743-1e63e3df7958 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a007f3aa-3977-4be3-a9a2-db3d458bca58 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bed63fb-91ec-4132-ac0a-16c4c6f58d95 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80fe034e-01b7-438e-8378-44fafb7a1d94 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32c4372e-54ea-4fc8-b9f8-827fa4c8edd3 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8e243c0-805a-4d81-bec9-f5be6eb9f2bc (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7c3c63e-3aea-4b33-b165-7c7449359674 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a29cf117-00d0-4948-b646-013c8791ea39 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:551918e1-96c4-453a-870c-61b282882206 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de008936-e8a3-4e65-bb6a-d925b68a5f50 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fb6d547-9966-4352-8974-d02ea58e6445 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:084b34ad-36ba-43bd-a43a-1f4b4da26d8f (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b92460e-48ba-44bb-9b61-5e65e5fd82cd (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5d87c7c-3d03-4a9a-8f07-382371c55169 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8914d8bf-61b7-4cd2-a8ef-7e1c5df37828 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06745425-e7e7-4413-b9ff-22b121f0ea9a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a9229c8-89ba-423e-8e36-f56bc329ed38 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:681b5e9d-e2c7-4f29-aaad-e06d4a528c11 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7cd724b-817b-4b45-8133-1ebf505867e7 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3d38c1d-9b35-478e-bc2f-3e82b09a1538 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b5450f2-ae91-48b6-ad83-261bdfcf47ac (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e47e7b1-d28a-4e12-882f-cf193b7f2697 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d85bbced-8a9e-414d-bc88-dd0b68c118df (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37179b2d-6589-40d8-8121-7561a6791d38 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c753aae-77b7-4add-8453-385a8f62d7db (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef5fe12a-f8ee-4ba7-932b-51bbaccf6575 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:308c690f-c2bd-4c32-8728-42ec95425f77 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f9dccf8-37ff-454b-9d55-7f1d631c8483 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a60bfe5f-d0d6-4d15-a3de-32dc68e41af3 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:525138cd-832a-41d0-84b0-83921b12bd2a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5a68154-8003-4b80-81e2-e926524fb72c (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c71a17e-ed76-4545-b23e-9f4997b13c2f (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87385a0a-e7e6-8b7f-e053-2991aa0aa21a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05cb961d-ac33-4bcf-b04e-411e496c43c1 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bd4fcd3-3020-41f2-b112-023b5db4487d (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:627c9732-eed1-4435-8d79-2e19ab974fd9 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c38a404d-a919-4a2c-9fbb-d0655dee9516 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a5577f5-d2fe-4b0d-8245-78ee77df30fd (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b338ae20-fc07-4ec5-9e68-be636f75ce1a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:387edfd4-be85-41cd-8a6d-14e6a022b5a9 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82eb62ca-c32b-4ff8-9f71-43219b240480 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6f12a41-ae6d-4ce6-9bb1-e32679af665f (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfa1f77d-8209-48e9-a6c7-d3b4725a97db (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7068f36-a863-4af0-9c82-e5394a6e7a54 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cddd33fb-25b0-49ca-ab32-7c79a9b3a384 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bd7a71e-0e78-dae7-e053-2995a90ad110 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6ff0d37-c67d-4b9f-8b62-5deda9783c28 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bcc6cdb-3dfa-4757-bac2-a2dc8bd3a9f6 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6f752c5-d2bd-4f77-9611-ca2110066d1f (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Distribution Bumetanide exhibits high plasma protein binding in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b5a38cc-1e76-4821-b286-31bad3bd6913 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43ab2dd6-39ba-4a53-aa84-d7975038ef43 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4688d53-9baf-4cf0-b37f-47779bce7815 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68f18d36-ffc2-4481-9286-914cfcf573a0 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff5dc8c6-b2f2-41d3-8e56-a953aa721b59 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein-binding is in the range of 94% to 96%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9058fc52-f3f6-4d7f-b2a0-b1e2c714b133 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Plasma protein binding is in the range of 94% to 96%.
Projected row 214
- Medicine slug
- bumetanide
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 74
- Source count
- 73
- Agreement rate
- 1
- Recorded readings
0.26 L/kg
- Numeric value
- 0.26
- Unit
- L/kg
- Source records
- 73
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 73 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae7dd557-f7a1-4d5a-b80e-3ca3a6e4943b (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4326e53-5217-48d4-a089-1184442049ac (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12b9489a-b16b-4504-a660-e66fd5261069 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf29e436-b630-4b03-bb9b-9267ae77dc00 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d1ed6b2-c410-4f52-9b8a-aa256c37089e (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e9633e4-151b-4f40-885e-8f364f6f2d18 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2dcdf9b-70b9-493f-99b4-fc7dcc31939a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e3d3ea1-830f-4fc6-9c56-b2ec71875dc6 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9188ab17-8539-48a5-905f-ad35ab5a0b93 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:056be255-5880-48e9-b160-bd5b3d82c24a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94078edd-b9c0-449e-baaf-a9afceccb407 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51d5f639-5d25-4ada-8bbe-ada2386173bf (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fb78afc-d8bc-4ae8-8c0a-6d9c6f7a22c5 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32dfbea3-eb2b-4070-8605-57ce3e6d5a2f (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14e92f79-2c7b-4ab9-844f-e7bd1964f8b2 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:680563fe-5d3a-49bc-86a5-740bda2acebe (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa4e5faf-c91a-457b-bd2b-14a9add51ac8 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4dd156d-0f17-43d9-bf78-2d358c50681b (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79b77945-74a7-4cb5-8aa0-33a7babdf6d9 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51a344b6-acf9-4ac4-b743-1e63e3df7958 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a007f3aa-3977-4be3-a9a2-db3d458bca58 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bed63fb-91ec-4132-ac0a-16c4c6f58d95 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80fe034e-01b7-438e-8378-44fafb7a1d94 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32c4372e-54ea-4fc8-b9f8-827fa4c8edd3 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8e243c0-805a-4d81-bec9-f5be6eb9f2bc (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7c3c63e-3aea-4b33-b165-7c7449359674 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates has been reported to range from 0.26 L/kg to 0.38 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a29cf117-00d0-4948-b646-013c8791ea39 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:551918e1-96c4-453a-870c-61b282882206 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de008936-e8a3-4e65-bb6a-d925b68a5f50 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fb6d547-9966-4352-8974-d02ea58e6445 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:084b34ad-36ba-43bd-a43a-1f4b4da26d8f (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b92460e-48ba-44bb-9b61-5e65e5fd82cd (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5d87c7c-3d03-4a9a-8f07-382371c55169 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8914d8bf-61b7-4cd2-a8ef-7e1c5df37828 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06745425-e7e7-4413-b9ff-22b121f0ea9a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a9229c8-89ba-423e-8e36-f56bc329ed38 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:681b5e9d-e2c7-4f29-aaad-e06d4a528c11 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates has been reported to range from 0.26 L/kg to 0.38 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7cd724b-817b-4b45-8133-1ebf505867e7 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3d38c1d-9b35-478e-bc2f-3e82b09a1538 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b5450f2-ae91-48b6-ad83-261bdfcf47ac (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e47e7b1-d28a-4e12-882f-cf193b7f2697 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d85bbced-8a9e-414d-bc88-dd0b68c118df (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37179b2d-6589-40d8-8121-7561a6791d38 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c753aae-77b7-4add-8453-385a8f62d7db (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef5fe12a-f8ee-4ba7-932b-51bbaccf6575 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:308c690f-c2bd-4c32-8728-42ec95425f77 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates has been reported to range from 0.26 L/kg to 0.38 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f9dccf8-37ff-454b-9d55-7f1d631c8483 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a60bfe5f-d0d6-4d15-a3de-32dc68e41af3 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:525138cd-832a-41d0-84b0-83921b12bd2a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5a68154-8003-4b80-81e2-e926524fb72c (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates has been reported to range from 0.26 L/kg to 0.38 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c71a17e-ed76-4545-b23e-9f4997b13c2f (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87385a0a-e7e6-8b7f-e053-2991aa0aa21a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05cb961d-ac33-4bcf-b04e-411e496c43c1 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bd4fcd3-3020-41f2-b112-023b5db4487d (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:627c9732-eed1-4435-8d79-2e19ab974fd9 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c38a404d-a919-4a2c-9fbb-d0655dee9516 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a5577f5-d2fe-4b0d-8245-78ee77df30fd (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b338ae20-fc07-4ec5-9e68-be636f75ce1a (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:387edfd4-be85-41cd-8a6d-14e6a022b5a9 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82eb62ca-c32b-4ff8-9f71-43219b240480 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6f12a41-ae6d-4ce6-9bb1-e32679af665f (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfa1f77d-8209-48e9-a6c7-d3b4725a97db (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7068f36-a863-4af0-9c82-e5394a6e7a54 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cddd33fb-25b0-49ca-ab32-7c79a9b3a384 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bd7a71e-0e78-dae7-e053-2995a90ad110 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates has been reported to range from 0.26 L/kg to 0.38 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6ff0d37-c67d-4b9f-8b62-5deda9783c28 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bcc6cdb-3dfa-4757-bac2-a2dc8bd3a9f6 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8b5a38cc-1e76-4821-b286-31bad3bd6913 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43ab2dd6-39ba-4a53-aa84-d7975038ef43 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4688d53-9baf-4cf0-b37f-47779bce7815 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68f18d36-ffc2-4481-9286-914cfcf573a0 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff5dc8c6-b2f2-41d3-8e56-a953aa721b59 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9058fc52-f3f6-4d7f-b2a0-b1e2c714b133 (opens source in a new tab)
Bumetanide label
Version not recorded · Effective date not recorded
Mean volume of distribution in neonates and infants has been reported to range from 0.26 L/kg to 0.39 L/kg.
Projected row 215
- Medicine slug
- bupivacaine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 46
- Source count
- 42
- Agreement rate
- 1
- Recorded readings
2.7 hours
- Numeric value
- 2.7
- Unit
- hours
- Source records
- 42
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 42 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e6a55f0-5107-4ea9-9ee1-5c6c09bbe4a6 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f9ebeef-350a-495e-a0bf-c335ab48bf1c (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f29c905e-9a55-446f-a89d-860ad9ade7ad (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1091d4d8-5dad-46e1-8f26-7bc0c5dd833f (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:950d82b6-76a1-0c08-e053-2a95a90a3a92 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
The half-life of Bupivacaine Hydrochloride in adults is 2.7 hours and in neonates 8.1 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8815c8c6-eed8-4afe-a5c1-44d2194025a3 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:100201ad-6e4d-4e91-8b5c-621d0bf0dcc2 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
The half-life of bupivacaine in adults is 2.7 hours and in neonates 8.1 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e391f807-7699-6d82-e053-2a95a90ab641 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
The half-life of bupivacaine in adults is 2.7 hours and in neonates 8.1 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8759cac8-d977-4c2a-814c-5b59f2f0c910 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1642239-4230-b679-e053-2a95a90a3b7c (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
The half-life of bupivacaine in adults is 2.7 hours and in neonates 8.1 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcaab86f-20f0-4482-8d73-e29b36dced58 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78c6789d-773e-4b26-90bd-34a6b6d730ce (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f37a19ad-5e69-44a8-947b-847df2106fb3 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e700eb7b-8b14-49c9-96b2-331f18776e45 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:496ccd9e-d1c3-4b5a-93b6-0c457faa1589 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f7ab295-6429-4760-e063-6294a90a781f (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e552e3a-cf52-4d74-9381-6cc1b29b4c90 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c6f9b85-e783-4ad4-a804-a0ff1a32ec2c (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2046d833-2974-42fd-a29e-7fc1dc7166cc (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a60303c2-5217-41db-855b-83fa2a749da2 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
The half-life of bupivacaine in adults is 2.7 hours and in neonates 8.1 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ada6a9bf-f7cb-035a-e053-2a95a90a6a3d (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
The half-life of Bupivacaine Hydrochloride in adults is 2.7 hours and in neonates 8.1 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:694926ac-aff0-aa1f-e053-2991aa0a9588 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
The half-life of bupivacaine in adults is 2.7 hours and in neonates 8.1 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:adadc041-8d5e-4bf8-a89b-e227729a880d (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f8f4ece-de78-4c13-8d9f-c3bb7053019d (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee3b5bbe-4013-4682-b6ee-db86e7788077 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3eefbefe-78ae-4f2d-9be6-3f79eadcff86 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
The half-life of bupivacaine in adults is 2.7 hours and in neonates 8.1 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06c15208-c600-7173-e063-6394a90a2f94 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f03f28d9-e42e-404d-9c9c-7707aedb478c (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3335dabe-66d5-440b-a59a-b62993030e0f (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4595c642-1869-436c-9550-8f9f255efd27 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dc693df-3218-4a90-b3f7-21e80966a851 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c0f567f-b7f8-4ee8-bfb2-61cd82550498 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb71b757-057e-42d4-8a12-8fd8e69a9124 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb44c7e1-d911-4788-908f-09b7b271969b (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:562f4499-f3b7-4d9e-b022-61172176c883 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe340f98-a0f3-446e-b281-47fd91c1e537 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e0cff98-ad0e-494d-8316-b7cdfad6a876 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6bfc04a-1868-4630-9ca1-8c027af97ce3 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
The half-life of bupivacaine in adults is 2.7 hours and in neonates 8.1 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42c973e2-307b-924c-e063-6394a90a737a (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8b32972-6984-4f1c-e053-2995a90a3277 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffecf450-1f01-4721-8e10-251385852612 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a996abe-0bb9-4590-e063-6394a90a0b60 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Elimination The half-life of bupivacaine in adults is 2.7 hours.
Projected row 216
- Medicine slug
- bupivacaine
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 46
- Source count
- 44
- Agreement rate
- 1
- Recorded readings
95%
- Numeric value
- 95
- Unit
- %
- Source records
- 44
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 44 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e6a55f0-5107-4ea9-9ee1-5c6c09bbe4a6 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f9ebeef-350a-495e-a0bf-c335ab48bf1c (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f29c905e-9a55-446f-a89d-860ad9ade7ad (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1091d4d8-5dad-46e1-8f26-7bc0c5dd833f (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:950d82b6-76a1-0c08-e053-2a95a90a3a92 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine Hydrochloride with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8815c8c6-eed8-4afe-a5c1-44d2194025a3 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:100201ad-6e4d-4e91-8b5c-621d0bf0dcc2 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e391f807-7699-6d82-e053-2a95a90ab641 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8759cac8-d977-4c2a-814c-5b59f2f0c910 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1642239-4230-b679-e053-2a95a90a3b7c (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcaab86f-20f0-4482-8d73-e29b36dced58 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78c6789d-773e-4b26-90bd-34a6b6d730ce (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f37a19ad-5e69-44a8-947b-847df2106fb3 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0af296bb-1599-4b35-b66b-994924d3e898 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e700eb7b-8b14-49c9-96b2-331f18776e45 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:496ccd9e-d1c3-4b5a-93b6-0c457faa1589 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f7ab295-6429-4760-e063-6294a90a781f (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e552e3a-cf52-4d74-9381-6cc1b29b4c90 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c6f9b85-e783-4ad4-a804-a0ff1a32ec2c (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2046d833-2974-42fd-a29e-7fc1dc7166cc (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a60303c2-5217-41db-855b-83fa2a749da2 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ada6a9bf-f7cb-035a-e053-2a95a90a6a3d (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine Hydrochloride with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:694926ac-aff0-aa1f-e053-2991aa0a9588 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:adadc041-8d5e-4bf8-a89b-e227729a880d (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f8f4ece-de78-4c13-8d9f-c3bb7053019d (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee3b5bbe-4013-4682-b6ee-db86e7788077 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb5a9e59-0f51-11df-8a39-0800200c9a66 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3eefbefe-78ae-4f2d-9be6-3f79eadcff86 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06c15208-c600-7173-e063-6394a90a2f94 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f03f28d9-e42e-404d-9c9c-7707aedb478c (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3335dabe-66d5-440b-a59a-b62993030e0f (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4595c642-1869-436c-9550-8f9f255efd27 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dc693df-3218-4a90-b3f7-21e80966a851 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c0f567f-b7f8-4ee8-bfb2-61cd82550498 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cb71b757-057e-42d4-8a12-8fd8e69a9124 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb44c7e1-d911-4788-908f-09b7b271969b (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:562f4499-f3b7-4d9e-b022-61172176c883 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe340f98-a0f3-446e-b281-47fd91c1e537 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e0cff98-ad0e-494d-8316-b7cdfad6a876 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6bfc04a-1868-4630-9ca1-8c027af97ce3 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42c973e2-307b-924c-e063-6394a90a737a (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8b32972-6984-4f1c-e053-2995a90a3277 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffecf450-1f01-4721-8e10-251385852612 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a996abe-0bb9-4590-e063-6394a90a0b60 (opens source in a new tab)
Bupivacaine label
Version not recorded · Effective date not recorded
Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4).
Projected row 217
- Medicine slug
- buprenorphine
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 48
- Source count
- 42
- Agreement rate
- 0.809524
- Recorded readings
31 to 35 hours
- Numeric value
- 31
- Unit
- hours
- Source records
- 34
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 34 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:655e3e52-03be-496c-978a-5cffc74b2ae4 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablet is administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2181e700-caa1-48c4-90ce-60fec053ba6a (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5479b218-a388-2c3c-e063-6294a90a0e85 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa86a438-1ebf-4c08-bf27-38f1e81efb3a (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03819118-86f6-4329-adaf-4599e7b71f46 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:023c7816-21b1-4f85-be36-9e32d5935c19 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablet is administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a7418a2-bd6e-4082-b0fe-a5498e7b944a (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When Buprenorphine is administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:966adb01-71b4-4e0b-bbc6-b83da9987aa2 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fd1f18f-0b0f-4059-b603-19ecbf0ed63a (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablet is administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1398d85-d4bb-4426-8ecf-a50400910d81 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f7b0a28-f937-4d4d-b793-ca3468bd28e0 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When Buprenorphine Sublingual Tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da90618a-5621-4b15-bc48-9dcc631418de (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bf8b35a-b769-465c-a2f8-099868dfcd2f (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When Buprenorphine Sublingual Tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa132031-9d12-45b4-81e0-4a5877661379 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5578cd5c-c860-6e8a-e063-6394a90a56c7 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfb02ea5-22f2-432e-afc8-f1dbe2ea0614 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d976ee7-9509-49da-89fd-48d7e712697b (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablet is administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:301eaed5-8499-ad95-e063-6294a90a58f5 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When Buprenorphine Sublingual Tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1408cd8f-a0b5-6be7-e063-6394a90a0b41 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablet is administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dba586f9-e3f2-4b9c-849b-907c81a5a0ef (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When Buprenorphine Sublingual Tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1aac2bb-cb83-46cb-9a29-502a62010667 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When Buprenorphine Sublingual Tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7da638f-f590-4577-bff9-15a91c6e7917 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:699638dd-3a53-445f-a545-d0e6eabfe1c9 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When Buprenorphine Sublingual Tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b60d514d-a88a-4fa2-a5b0-30ac29e04973 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd0a90c6-32cc-4114-8573-86ac85503bdf (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69a647c0-bc09-4ee2-aeb3-ef286caf25e5 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When Buprenorphine Sublingual Tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:325532f0-276f-4689-97d6-cda879b4c758 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5a8c41e-413e-4d48-9739-d158e5681dd0 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When Buprenorphine Sublingual Tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11686845-f5fd-4e96-8a4f-9b132bf48840 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc5a7137-9e8f-438e-84d9-bdbf1db12998 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d38f7aa-da0b-40ad-b0d1-4284c71042ed (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dd00186-1f1f-642a-e063-6294a90a6d20 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablet is administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b52cea0e-688f-4beb-bf7d-f228b81dbd23 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:442831cf-9636-433a-9a12-e9a8cd31f72a (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
When buprenorphine sublingual tablets are administered sublingually, buprenorphine has a mean elimination half-life from plasma ranging from 31 to 35 hours.
26 hours
- Numeric value
- 26
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
After removal of buprenorphine transdermal system, mean buprenorphine concentrations decrease approximately 50% within 10 to 24 hours, followed by decline with an apparent terminal half-life of approximately 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7d079fb-507f-436f-b794-2171b7d97067 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
After removal of buprenorphine transdermal system, mean buprenorphine concentrations decrease approximately 50% within 10 to 24 hours, followed by decline with an apparent terminal half-life of approximately 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36995ce3-b515-447b-baa9-aa14f84060d8 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
After removal of buprenorphine transdermal system, mean buprenorphine concentrations decrease approximately 50% within 10 to 24 hours, followed by decline with an apparent terminal half-life of approximately 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2738feae-316e-426f-971c-5f142ac01b60 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
After removal of buprenorphine transdermal system, mean buprenorphine concentrations decrease approximately 50% within 10 to 24 hours, followed by decline with an apparent terminal half-life of approximately 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:794aa355-66de-41b8-aedf-f2c40f6bc664 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
After removal of BUTRANS, mean buprenorphine concentrations decrease approximately 50% within 10-24 hours, followed by decline with an apparent terminal half-life of approximately 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:315284b8-32ab-d34a-ea02-f501c6131bcc (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
After removal of buprenorphine transdermal system, mean buprenorphine concentrations decrease approximately 50% within 10 to 24 hours, followed by decline with an apparent terminal half-life of approximately 26 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1aae9b13-7431-42ef-8558-14a2325820e6 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
After removal of buprenorphine transdermal system, mean buprenorphine concentrations decrease approximately 50% within 10 to 24 hours, followed by decline with an apparent terminal half-life of approximately 26 hours.
27.6±11.2 hours
- Numeric value
- 27.6
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc2b7a3d-72cf-497c-95b0-ba2b71f63c64 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
Based on multiple-dose studies performed with BELBUCA, the mean plasma elimination half-life of buprenorphine was 27.6±11.2 hours.
Projected row 218
- Medicine slug
- buprenorphine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 48
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
24 hours
- Numeric value
- 24
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6189fb21-9432-45f8-8481-0bfaf3ccde95 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
After SUBLOCADE injection, an initial buprenorphine peak was observed and the median T max occurred at 24 hours after injection.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d8a8fd0-8619-422a-a664-d1d2e8970f48 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
After BRIXADI subcutaneous injection, the buprenorphine plasma concentration increases with a median time to maximum plasma concentration (t max ) of about 24 hours for BRIXADI (weekly) and 6-10 hours for BRIXADI (monthly).
Projected row 219
- Medicine slug
- buprenorphine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 48
- Source count
- 7
- Agreement rate
- 1
- Recorded readings
430 L
- Numeric value
- 430
- Unit
- L
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:186e3be6-8bc0-4bb9-96f5-429d53632f45 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
Studies of IV buprenorphine have shown a large volume of distribution (approximately 430 L), implying extensive distribution of buprenorphine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7d079fb-507f-436f-b794-2171b7d97067 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
Studies of IV buprenorphine have shown a large volume of distribution (approximately 430 L), implying extensive distribution of buprenorphine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36995ce3-b515-447b-baa9-aa14f84060d8 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
Studies of IV buprenorphine have shown a large volume of distribution (approximately 430 L), implying extensive distribution of buprenorphine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2738feae-316e-426f-971c-5f142ac01b60 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
Studies of IV buprenorphine have shown a large volume of distribution (approximately 430 L), implying extensive distribution of buprenorphine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:794aa355-66de-41b8-aedf-f2c40f6bc664 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
Studies of IV buprenorphine have shown a large volume of distribution (approximately 430 L), implying extensive distribution of buprenorphine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:315284b8-32ab-d34a-ea02-f501c6131bcc (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
Studies of IV buprenorphine have shown a large volume of distribution (approximately 430 L), implying extensive distribution of buprenorphine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1aae9b13-7431-42ef-8558-14a2325820e6 (opens source in a new tab)
Buprenorphine label
Version not recorded · Effective date not recorded
Studies of IV buprenorphine have shown a large volume of distribution (approximately 430 L), implying extensive distribution of buprenorphine.
Projected row 220
- Medicine slug
- bupropion
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 251
- Source count
- 131
- Agreement rate
- 1
- Recorded readings
5%
- Numeric value
- 5
- Unit
- %
- Source records
- 131
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 131 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:507112bd-a082-e85a-e063-6294a90ab2ac (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13560bf8-eb25-44f0-968e-db70d51219af (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:144379e1-93b7-41c1-bc3a-7bdec5afa309 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1094ff8e-f5a5-4a72-8bf9-25e68f5c964a (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86530199-999b-9f92-b1bc-b8515ec829f3 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeb3fed1-2202-09fc-e053-2995a90a9f63 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9196568e-aec8-4d56-993e-4cbb78d4a3a6 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b73d56e-e558-49de-8126-d7ec9b67a086 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcb4ef83-f272-4090-8547-9aaf4ab63667 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d86e26e0-6e10-4d59-8cc8-94b551774b86 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b127d3fc-be5e-4c12-8026-205766bf8e7f (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef0bb8f2-7710-4236-8b47-57b74c8bca3e (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:850ac56a-ba50-4e61-b1ee-805e17735b5c (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21be6b3b-add3-43e7-af93-30350aefc89e (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cec41945-8d64-4793-8784-4c2b8ec37b0f (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b47c5515-a438-40bc-b8ad-26a6cf9676b7 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:161637d2-bc9d-4a2b-ad1f-6cc39ffd69ce (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:093c4a61-02d9-4b55-b612-569aa25d3f2a (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b3939b-a410-6354-e053-2995a90ababb (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0574b84d-075f-410f-a8eb-86901e307ea2 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78ef709a-f835-4b03-92dd-16a4c82af0c1 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:500fc18d-93b4-47d5-a3f7-3f68822d83e8 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:634bc654-be95-4fea-b308-eed53269a112 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:744f7394-aac9-4864-9436-e5b0b35a6148 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0aa86bd6-b37b-45f7-a837-b067e41184e9 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:990587bd-4c7d-4a36-8a38-3104648ab3a2 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab6cd2ea-507c-35e5-e053-2a95a90ac5cb (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67b6bcf8-0e7c-4e74-ad72-54f1bd6e65ad (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:434aacf8-87f1-44fc-a66b-92ae0022de0e (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:362504fd-2f0a-c097-e063-6394a90ac0fc (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a72db723-df4b-4bf4-9bdc-05ae82058696 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bb61b34-653a-43b4-9682-705d5b82d18e (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eabb54b7-164c-4de8-b91a-f2e65637b5fc (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f86f677-2ebd-43c4-b2dd-2e07d4d54147 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aef84c3a-68e2-e9d9-e053-2995a90a4ab8 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87dac2ee-732c-465b-8ffe-e5aeba421425 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d2c209b-248e-4e26-9cde-fe0abe4428c1 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfb45438-1116-48f2-9bfe-776ebbf1e119 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:994229b0-e190-49e3-83ce-6a2063f7335a (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81d251aa-a8e8-493e-94ed-12f6fb8902e6 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33210109-2ddb-4b0f-a45e-988e493ca628 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f58ce435-b124-4519-98d8-de2d00f61b01 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c111cf0-0199-4a4d-8138-81579af4c14d (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30c5b97c-b19d-4d27-bb1a-ab19b7dfccaa (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b33fb1f-a7f0-4ab7-a882-eca2d2c77afa (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9490d611-b679-45c7-e053-2a95a90afb87 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa5fa0d8-d27f-44e1-8868-dfa7206524e2 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:909204fc-ff55-43d9-b9ee-e607ef60965e (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:339c7157-1c65-40d1-bbcc-c10348d908d3 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73167de9-948d-465c-88c0-c7743a79e7f5 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec8c699f-a8de-4e5a-a223-8de3f5dfe20d (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a724b3b6-f60e-4b88-8603-8141a32075da (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bd2ed35-35c5-464f-bf51-9dd4b42ee59a (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a591e33a-52f0-41c8-a00b-4a1afcc3dc4c (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0445fea-108f-4e00-a2ae-ebbdf2719947 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c37bb183-f272-4cae-96e1-7042c1dd7bcf (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6701af43-bf7d-45c4-a331-a18d16bd68f7 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbb587fa-75c0-4f4d-8eaf-f0e7ba8b5c75 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbc8c074-f080-4489-a5ae-207b5fadeba3 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d035056-44ab-444d-9d27-125b3f571140 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5d55b0c-8b81-476a-994e-1989e2a56255 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a165869a-9bc4-4987-babe-a77fad78c38f (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6563b923-269f-40c3-b992-cbacdfca6e16 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5d774dd-0f51-4a4f-a9d1-8b5f2364b1f7 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8069c521-c49a-4b6d-baa8-4b0be897d585 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29848192-7de3-4c0d-a822-1268dcf128b0 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c6b5ab4-9671-4fcd-8b4c-7f230dcfe6c9 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4fbe64aa-f8f4-45fa-88ae-e844997703ae (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1af890f7-1db8-4dd2-bf66-2b1e0c93a3d8 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5604eb14-bab4-4f06-e063-6294a90a6920 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39b2d509-1281-4464-9cf1-a94bbc18b84b (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9bbacb3-63b4-2922-e053-2a95a90a6085 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2a988f2-f8d3-4de0-b9f1-49d8c2e4180f (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3eec57be-b8ae-cdf8-e063-6394a90a694d (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd99969d-03d5-4609-88e8-a9ae93a83907 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e962fb9a-d9fb-49c5-a8b4-0b355b8f829b (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b59d950c-341f-45f1-b5b2-d64ccc799580 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d80f882-1887-4d73-b09f-e98fd7ef2acb (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0e10a21-0ae3-4a8b-bd3e-7a48b30f8418 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4971c3cb-07c4-4c65-a16a-f1700e523147 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a3b97be-afa3-49e6-962f-662b6807e607 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:092da413-ec60-4577-ac57-51e3e42d55c9 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d0608a1-0cc8-491a-ad91-238e0ea009fe (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6087100f-3ba4-412e-b08d-768d1dcdaf00 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1d1ed19-e111-4652-a0d4-9406e6f73e9f (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f69b322b-93ab-407a-bf25-fe13c6896ca6 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c76f2f9f-3999-4bdd-8ec3-e0066318d378 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:334e5635-e4cc-cf2a-e063-6294a90ae1e1 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5038440c-1f32-715a-e063-6294a90a889d (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d722dc2-7909-454e-b989-095677079044 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13770e60-117c-4814-93bb-9bc41a042a20 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d81ed30-ddf7-431a-84f8-6c630cf2b977 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1fa6fce-272b-4497-a958-177f0bafdfc7 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f820ad7d-3c88-4a4f-e053-6294a90aef7b (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38f52cec-9534-dab8-e063-6294a90a0704 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90cc4f07-e0a3-4d50-a10a-8f6a7f9c5140 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4100232-a25d-4468-9057-af7e66205154 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec4d2256-0340-4166-90ee-c264eef3ac82 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64934ca2-5655-45a2-9016-ad65b5abf5d3 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:620fab1e-aafb-444d-ab81-63281cd139c5 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88c980c8-aaa8-4378-9ac2-24d588640caa (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0865f8cf-1d7f-0e67-e063-6294a90a2f4d (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f8b3313-0286-499f-9235-02cdc0eb063b (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0eada89-e302-4ba3-bef0-e8c69af8206e (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c4313fa-bb29-dd50-e053-2991aa0a3005 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a13267f-c47f-4791-a8f9-4bbb5c804027 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96d87edc-d12b-44b2-e053-2995a90a4e63 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61e9cbe3-8211-42f3-b68f-581f56651919 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b303a0ad-5971-44ab-937c-bcf3ff650358 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e4c450ff-32bd-4359-8449-0b0d0b89a78c (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f56ccdb1-f9d9-3e5f-e053-2995a90a8f16 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bd469b8-fb35-0223-e063-6294a90ae7bc (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd153957-ff74-4134-8545-cdc0e5619906 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad784c8e-7201-4336-a310-616e3e979ca4 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c9a5dc3-bebe-431a-b550-ce46c6c6b01e (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:867d3876-6974-4e89-bc45-9e60e84b401c (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:439a7e93-f578-434f-943f-4b93c35450f5 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6948f63b-599c-4956-a249-e9544beda9fc (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8ad76a2-9f75-4660-973d-34402f314e9c (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f566f8b5-b3c1-4234-88bd-59a7b8dc801a (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35a873c5-4aa8-b3c7-e063-6394a90a35ec (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0961f83e-25e9-4ffc-8669-44e4e9169978 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5c12c9a-62eb-481a-8099-7ad35242f7bf (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fb44e96-6160-4a4a-90cb-91764c0dcd89 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5829a2aa-4845-b58b-e063-6294a90ad2f4 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6dc4a55b-c0c0-4cbe-988e-da81f0c4f75e (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ded4fa6-e637-4d59-a1b1-286854d4fe3a (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb63261f-ad18-4885-9ed7-e7dfde33e171 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1043c87-0abe-ee8e-e053-2a95a90a419a (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47b96919-a8ea-b769-e063-6394a90aa34e (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:350336bf-57b1-4d2f-bf25-956bb6023c07 (opens source in a new tab)
Bupropion label
Version not recorded · Effective date not recorded
In rat and dog studies, the bioavailability of bupropion ranged from 5% to 20%.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=210Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.